Navigation Links
UCB and Amgen Initiate Sclerostin Antibody Phase 3 Program in Patients With Postmenopausal Osteoporosis
Date:4/3/2012

.

In addition, sales of our products are affected by the reimbursement policies imposed by third-party payers, including governments, private insurance plans and managed care providers and may be affected by regulatory, clinical and guideline developments and domestic and international trends toward managed care and healthcare cost containment as well as U.S. legislation affecting pharmaceutical pricing and reimbursement. Government and others' regulations and reimbursement policies may affect the development, usage and pricing of our products. In addition, we compete with other companies with respect to some of our marketed products as well as for the discovery and development of new products. We believe that some of our newer products, product candidates or new indications for existing products, may face competition when and as they are approved and marketed. Our products may compete against products that have lower prices, established reimbursement, superior performance, are easier to administer, or that are otherwise competitive with our products. In addition, while we routinely obtain patents for our products and technology, the protection offered by our patents and patent applications may be challenged, invalidated or circumvented by our competitors and there can be no guarantee of our ability to obtain or maintain patent protection for our products or product candidates. We cannot guarantee that we will be able to produce commercially successful products or maintain the commercial success of our existing products. Our stock price may be affected by actual or perceived market opportunity, competitive position, and success or failure of our products or product candidates. Further, the discovery of significant problems with a product similar to one of our products that implicate an entire class of products could have a material adverse effect on sales of the affected products and on our business and results of operations.

The scientific informatio
'/>"/>

SOURCE Amgen
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Arthritis Foundation Announces Amgen and Wyeth to Be Presenting Sponsor of the 2008 Arthritis Walk (R)
2. Medarex to Receive Milestone Payment from Amgen
3. AMT Obtains License to Amgens GDNF Gene to Develop Treatment for Parkinsons Disease with AMTs Proprietary Gene Therapy Platform
4. Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung Cancer
5. CDC Foundation Partners with Amgen, CDC to Reduce Infections Among Cancer Patients
6. Amgen Announces Positive Top-Line Results for Denosumab in Trial for Delay of Skeletal Related Events in Bone Metastases Patients Compared to Zometa(R)
7. Amgen Issues Statement on Outcomes of Advisory Committee for Reproductive Health Drugs (ACRHD) Meeting
8. Amgen Announces Top-Line Results of Trial to Reduce Cardiovascular Events With Aranesp(R) Therapy (TREAT) in CKD Patients With Type-2 Diabetes
9. Amgen Presents Data From First Nplate(R) Study in Children With Chronic ITP
10. Amgen Highlights Data to be Presented at American Society for Bone and Mineral Research (ASBMR) Meeting
11. Amgen Board Authorizes $5 Billion Increase in Stock Repurchase Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/1/2014)... Arena Pharmaceuticals, Inc. (NASDAQ: ARNA ) ... results for the second quarter ended June 30, ... see encouraging advancements in the US commercialization of ... total prescriptions and estimated total per week prescriptions ... President and Chief Executive Officer. "Other recent notable ...
(Date:7/31/2014)... MONROVIA, Calif., July 31, 2014 STAAR Surgical ... manufacturer and marketer of implantable lenses and delivery systems ... quarter ended July 4, 2014 of $20.0 million, a ... quarter of 2013. On a constant currency basis, revenues ... to the second quarter of 2013.  The effect of ...
(Date:7/31/2014)... 31, 2014 Pharmacyclics, Inc. (the "Company") (Nasdaq: ... for the quarter ended June 30, 2014. Financial ... 2014 Revenue Total revenue for the quarter ended June ... the quarter ended June 30, 2013 primarily due to IMBRUVICA ... Total revenue for the six months ended June ...
Breaking Medicine Technology:Arena Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2014 Financial Results 2Arena Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2014 Financial Results 3Arena Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2014 Financial Results 4Arena Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2014 Financial Results 5Arena Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2014 Financial Results 6Arena Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2014 Financial Results 7Arena Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2014 Financial Results 8Arena Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2014 Financial Results 9Arena Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2014 Financial Results 10Arena Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2014 Financial Results 11STAAR Surgical Reports 10% Second Quarter Revenue Growth 2STAAR Surgical Reports 10% Second Quarter Revenue Growth 3STAAR Surgical Reports 10% Second Quarter Revenue Growth 4STAAR Surgical Reports 10% Second Quarter Revenue Growth 5STAAR Surgical Reports 10% Second Quarter Revenue Growth 6STAAR Surgical Reports 10% Second Quarter Revenue Growth 7STAAR Surgical Reports 10% Second Quarter Revenue Growth 8STAAR Surgical Reports 10% Second Quarter Revenue Growth 9STAAR Surgical Reports 10% Second Quarter Revenue Growth 10STAAR Surgical Reports 10% Second Quarter Revenue Growth 11STAAR Surgical Reports 10% Second Quarter Revenue Growth 12STAAR Surgical Reports 10% Second Quarter Revenue Growth 13STAAR Surgical Reports 10% Second Quarter Revenue Growth 14STAAR Surgical Reports 10% Second Quarter Revenue Growth 15STAAR Surgical Reports 10% Second Quarter Revenue Growth 16STAAR Surgical Reports 10% Second Quarter Revenue Growth 17STAAR Surgical Reports 10% Second Quarter Revenue Growth 18STAAR Surgical Reports 10% Second Quarter Revenue Growth 19STAAR Surgical Reports 10% Second Quarter Revenue Growth 20STAAR Surgical Reports 10% Second Quarter Revenue Growth 21STAAR Surgical Reports 10% Second Quarter Revenue Growth 22STAAR Surgical Reports 10% Second Quarter Revenue Growth 23STAAR Surgical Reports 10% Second Quarter Revenue Growth 24STAAR Surgical Reports 10% Second Quarter Revenue Growth 25STAAR Surgical Reports 10% Second Quarter Revenue Growth 26
... 2010 Market Publishers Ltd informs that new in-demand ... been added to its catalogue. ... Devices 2011 . In 2010, the ... and ablation devices were valued at over $1.4 billion. ...
... Dec. 16, 2010 Solta Medical, Inc. (Nasdaq: ... tightening and a market leader in aesthetic skin treatments, today ... revolutionary Thermage and Fraxel devices that have helped to build ... device industry. The milestone reflects how much the ...
Cached Medicine Technology:New Topical Research Reports by iData Research Published by MarketPublishers.com 2New Topical Research Reports by iData Research Published by MarketPublishers.com 3Solta Medical Ships One Millionth Tip for Thermage and Fraxel Devices 2Solta Medical Ships One Millionth Tip for Thermage and Fraxel Devices 3
(Date:8/1/2014)... of electronic reminders such as text messages, emails or ... adhere to a preadmission antiseptic showering regimen known to ... to a first-of-its-kind study published in the August issue ... Surgeons . , Each year approximately 400,000 SSIs occur ... according to data sources cited by study authors. ...
(Date:8/1/2014)... CO (PRWEB) August 01, 2014 According to ... onto the Internet do so in search of information, and ... website, those in search of information and resources on insurance ... , “We're excited to take this next step in the ... DCInsurers Colorado Springs - Commercial Insurance Resources office. ...
(Date:8/1/2014)... Home Care Assistance of Cincinnati , a ... be recognized as a 2014 Best of Home Care Employer ... providers who rank in the top 50th percentile in one ... conducted by Home Care Pulse. , “The Best of ... best of the best!” says Home Care Pulse Founder and ...
(Date:8/1/2014)... Ticket Down is a reputable source for ... in Knoxville/Greenback, TN; Ingram Farms in Auburn/Opelika, AL; Cross Creek ... FL. Luke Bryan is currently out on his summer “That’s ... Swindell. Bryan is responsible for one of the most popular ... year, just because the summer is over doesn’t mean that ...
(Date:8/1/2014)... Researchers and doctors at the Institute of Bioengineering ... National Cancer Centre Singapore (NCCS) have co-developed the ... and survival outcomes in kidney cancer patients. This ... , the world,s top urology journal. , ... Ying, "By combining our expertise in molecular diagnostics ...
Breaking Medicine News(10 mins):Health News:Electronic reminders can help patients prevent surgical site infections 2Health News:Electronic reminders can help patients prevent surgical site infections 3Health News:DCInsurers Agent Doug King Launches a New Website 2Health News:DCInsurers Agent Doug King Launches a New Website 3Health News:Cincinnati Senior Care Company Receives 2014 Best of Home Care® Employer of Choice Award 2Health News:Luke Bryan Tickets at Maple Lane Farms in Knoxville, Ingram Farms in Auburn, Cross Creek Place in Tallahassee & Whitehurst Cattle Farm in Gainesville Now Available 2Health News:Luke Bryan Tickets at Maple Lane Farms in Knoxville, Ingram Farms in Auburn, Cross Creek Place in Tallahassee & Whitehurst Cattle Farm in Gainesville Now Available 3Health News:Luke Bryan Tickets at Maple Lane Farms in Knoxville, Ingram Farms in Auburn, Cross Creek Place in Tallahassee & Whitehurst Cattle Farm in Gainesville Now Available 4Health News:Taking the guesswork out of cancer therapy 2Health News:Taking the guesswork out of cancer therapy 3
... World Health Organization (WHO), is calling for renewed vigilance against ... Korea, Hong Kong, Indonesia and Vietnam have been reported. There’s ... was probably due to a mutated H5N1 virus that could ... pandemic is overdue and could happen during the winter months. ...
... come out with findings from a study that indicates ... celexa in combating// depression. ,Dr. Fran?ois Lespérance, ... colleagues published their findings in this week’s edition of ... ,The drug celexa, which goes by the generic name ...
... Bilcare, a leading research-based pharmaceutical packing solution ... with Honeywell//, a UK-based pharma packaging firm, ... pharmaceutical sector. ,"The partnership with Honeywell's ... provide state-of-the-art materials for ensuing safety of ...
... maternal DNA in the blood of around 20% of children ... also seemed to help in producing insulin, which is not ... to restore damaged tissue in the pancreas. They also found ... immune system. ,During pregnancy, stem cells of ...
... the high prevalence of HIV/AIDS in Karnataka and hoping to ... Kumaraswamy will spend Tuesday night in the hut of a ... in Bagalkot district, 600 km from the state capital Bangalore ... around 11 p.m. and spend the night in the house ...
... coffee could help cure baldness as caffeine blocks the effects ... ,Tobias Fischer of the University of Jena in Germany took ... hair loss. He extracted hair follicles and placed them in ... ,The samples were left in the laboratory for ...
Cached Medicine News:Health News:Are We Prepared for Flu Pandemic? 2Health News:Citalopram, a Boon in Treating Depressed Heart Patients 2Health News:Karnataka Chief Minister to Spend Night With HIV Positive Family 2
... Bulb Direct has been selling ... since 1996, and we are ... satisfaction guarantee. Check out our ... see our discount light bulbs ...
With the Symphony family of Pacemakers, Ela presents the most advanced technology on the market. Symphony, lighter than a passport, will take your patients further, offering fast follow-up, using new...
With the Symphony family of Pacemakers, Ela presents the most advanced technology on the market. Symphony, lighter than a passport, will take your patients further, offering fast follow-up, using new...
.90mm (20G) guillotine cutting probe with 1.4mm (17G) removable irrigation sleeve...
Medicine Products: